PATENT CLAIM ANALYSIS

Application Number: 16246422
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "588000"]

Abstract:
The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

Claim (Index 13):
A pharmaceutical composition for treating a cancer expressing prostate specific membrane antigen (\u201cPSMA\u201d), the composition comprising an effective amount of the compound of  claim 6  for treating the cancer and a pharmaceutically acceptable excipient wherein the cancer is non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer

Metadata:
- Claim Count in Document: 47.0
- Percentile: 99.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15630808', '15515056', '15314851', '09961969', '11834473']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7678290891047548
- 35 USC 102 Novelty (BERT): 0.5453944120773676
- Combined Prediction Score: 0.7455856214020161
- Mean Citation Score: 290.213182
- Max Citation Score: 402.75586
- Similarity Product: 326.97557305888773

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test